HC Wainwright & Co. analyst Raghuram Selvaraju maintains Oramed Pharmaceuticals (NASDAQ:ORMP) with a Buy and raises the price target from $17 to $32.
HC Wainwright & Co. Maintains Buy on Oramed Pharmaceuticals, Raises Price Target to $32
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Oramed Pharmaceuticals (NASDAQ:ORMP) with a Buy and raises the price target from $17 to $32.
Related Posts
‘Sports Illustrated To Launch Betting App In Colorado’ -Forbes
https://www.forbes.com/sites/willyakowicz/2021/09/01/sports-illustrated-branded-betting-app-to-launch-in-colorado/?sh=63a2f4517956&utm_medium=social&utm_source=ForbesMainTwitter&utm_campaign=socialflowForbesM
Penn National Q3 Earnings Highlights: Revenue Beat, Barstool Sportsbook In 10 States, Omnichannel Growth
Regional casino and sports betting company Penn National Gaming Inc (NASDAQ: PENN) announced third-quarter financial results before market open Thursday. Here are the highlights from the report.
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $7,500 Today
Ecolab (NYSE:ECL) has outperformed the market over the past 20 years by 2.57% on an annualized basis producing an average annual return of 10.64%. Currently, Ecolab has a market capitalization of $44.95 billion.